Sol-Gel Technologies (SLGL) Total Debt (2016 - 2017)
Sol-Gel Technologies (SLGL) reported Total Debt of $65.3 million for Q4 2017, up 74.99% year-over-year from $37.3 million in Q4 2016, and up 74.99% on a QoQ basis from $37.3 million in Q4 2016.
Sol-Gel Technologies (SLGL) has 2 years of Total Debt data on file, last reported at $65.3 million in Q4 2017.
- Quarterly Total Debt rose 74.99% year-over-year to $65.3 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $65.3 million (up 74.99% YoY) and the FY2017 annual result came in at $65.3 million, up 74.99% from the prior year.
- Total Debt climbed to $65.3 million in Q4 2017 per SLGL's latest filing, from $37.3 million in the prior quarter.
- Across five years, Total Debt topped out at $65.3 million in Q4 2017 and bottomed at $37.3 million in Q4 2016.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 110.96 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Sol-Gel Technologies | 205.76 Mn | 194.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2017 | 65.34 Mn |
| Dec 31, 2016 | 37.34 Mn |